相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patients with major depressive disorder have lower cerebral serotonin 4 receptor binding than healthy controls
K. Koehler-Forsberg et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)
Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials
Chi-Un Pae et al.
CNS SPECTRUMS (2014)
Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Leslie Citrome et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Safety of Selegiline Transdermal System in Clinical Practice: Analysis of Adverse Events From Postmarketing Exposures
Chi-Un Pae et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
The Transdermal Delivery System of Monoamine Oxidase Inhibitors
Chad M. VanDenBerg
JOURNAL OF CLINICAL PSYCHIATRY (2012)
If at First You Don't Succeed A Review of the Evidence for Antidepressant Augmentation, Combination and Switching Strategies
K. Ryan Connolly et al.
DRUGS (2011)
The Small Specific Effects of Antidepressants in Clinical Trials: What Do They Mean to Psychiatrists?
Michael E. Thase
CURRENT PSYCHIATRY REPORTS (2011)
Selegiline transdermal system: a novel treatment option for major depressive disorder
Jayasree J. Nandagopal et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants
Stephen M. Stahl et al.
CNS SPECTRUMS (2008)
Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): A comparison with oral selegiline capsules
Albert J. Azzaro et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Selegiline transdermal system in the prevention of relapse of major depressive disorder - A 52-week, double-blind, placebo-substitution, parallel-group clinical trial
Jay D. Amsterdam et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects
Albert J. Azzaro et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Transdermal selegiline: Targeted effects on monoamine oxidases in the brain
L Wecker et al.
BIOLOGICAL PSYCHIATRY (2003)
分享论文
